Physician profile
Gregory D Nanney
NPI 1780784645
$7,377.95
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,949 · 2020: $2,339 · 2021: $1,669 · 2022: $96.52 · 2023: $204 · 2024: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $218.27 |
| Education | $105.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,125.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $531.87 | 2019-2022 | |
| Seagen INC. | $510.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $475.99 | 2019-2023 | |
| Beigene, LTD. | $450.00 | 2020 | |
| Amgen INC. | $437.18 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $397.15 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $351.01 | 2019-2021 | |
| Astellas Pharma US INC | $335.19 | 2019-2021 | |
| Eisai INC. | $168.14 | 2019-2021 | |
| Lilly USA, LLC | $147.42 | 2019-2024 | |
| Tersera Therapeutics LLC | $137.26 | 2019-2021 | |
| Genzyme Corporation | $129.69 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $118.45 | 2019-2021 | |
| Epizyme, INC. | $114.34 | 2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Nanney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.